Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00112723 · OUTCOME

Lymphoid/Plasma Cell Malignancies

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · Source last updated 2016-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
patients
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.

Analysis population: Response indicated for Indolent B-cell NHL, Mantle cell NHL and T-cell NHL

Groups in this outcome

Cohort 1

Patients diagnosed with Indolent B-cell NHL

Cohort 2

Patients diagnosed with Mantle Cell NHL

Cohort 4

Patients diagnosed with T Cell NHL

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 113
Cohort 26
Cohort 46

Reported measurements

Partial Response
Values in patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 13Not reportedNot reportedNot reportedNot reported
Cohort 22Not reportedNot reportedNot reportedNot reported
Cohort 40Not reportedNot reportedNot reportedNot reported
Stable Disease
Values in patients · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort 10Not reportedNot reportedNot reportedNot reported
Cohort 20Not reportedNot reportedNot reportedNot reported
Cohort 43Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        0
    title
    Partial Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        3
    title
    Stable Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    2. group Id
      OG001
      value
      6
    3. group Id
      OG002
      value
      6
    units
    Participants
description
Identify subsets, based on levels of response (PR and SD), of lymphoid / plasma cell malignancies that are suitable for larger phase II studies designed to further evaluate the efficacy and toxicity of flavopiridol.
groups
  1. description
    Patients diagnosed with Indolent B-cell NHL
    id
    OG000
    title
    Cohort 1
  2. description
    Patients diagnosed with Mantle Cell NHL
    id
    OG001
    title
    Cohort 2
  3. description
    Patients diagnosed with T Cell NHL
    id
    OG002
    title
    Cohort 4
param Type
NUMBER
population Description
Response indicated for Indolent B-cell NHL, Mantle cell NHL and T-cell NHL
reporting Status
POSTED
time Frame
Up to 2 years
title
Lymphoid/Plasma Cell Malignancies
type
PRIMARY
unit Of Measure
patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice